Disclaimer: This information is intended for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare professional, considering the individual patient's circumstances and current clinical guidelines. While every effort has been made to ensure accuracy, medical knowledge is constantly evolving, and guidelines change. Always refer to the most current, official guidelines and expert consensus.

Meningitis

Overview

• Definition: Meningitis is an inflammatory condition of the meninges, which are the protective membranes that surround the brain and spinal cord. It is typically caused by an infection of the cerebrospinal fluid (CSF) and the subarachnoid space.
• Epidemiology:
  • Bacterial Meningitis: A medical emergency with high morbidity and mortality. Incidence has significantly decreased in many developed countries due to widespread vaccination programs (e.g., Haemophilus influenzae type b, Streptococcus pneumoniae, Neisseria meningitidis). Global incidence is estimated at 1.2 million cases annually, resulting in 170,000 deaths.
    • Pathogens by Age Group:
      • Neonates (<1 month): Group B Streptococcus (GBS), Escherichia coli, Listeria monocytogenes.
      • Infants/Children (1 month - 5 years): Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae type b (rare with vaccination).
      • Children/Adolescents (5 - 18 years): Neisseria meningitidis, Streptococcus pneumoniae.
      • Adults (18 - 50 years): Streptococcus pneumoniae, Neisseria meningitidis.
      • Older Adults (>50 years) & Immunocompromised: Streptococcus pneumoniae, Listeria monocytogenes, Gram-negative bacilli.
  • Viral Meningitis (Aseptic Meningitis): Much more common than bacterial, typically less severe, and often self-limiting. Enteroviruses (e.g., Coxsackieviruses, Echoviruses) are the most common cause, especially in summer and fall. Other causes include herpes simplex virus (HSV), varicella-zoster virus (VZV), mumps virus, HIV, arboviruses.
  • Other Types: Fungal (e.g., Cryptococcus neoformans in immunocompromised), parasitic, tuberculous, chemical, neoplastic, drug-induced. These are less common but important to consider in specific clinical contexts.
• Classification:
  • By Etiology:
    • Infectious: Bacterial, Viral, Fungal, Parasitic, Tuberculous.
    • Non-infectious: Drug-induced (e.g., NSAIDs, trimethoprim-sulfamethoxazole, IVIG), neoplastic (carcinomatosis), autoimmune/inflammatory (e.g., SLE, Behçet's disease, sarcoidosis).
  • By Course:
    • Acute: Symptoms evolving over hours to several days.
    • Subacute: Symptoms evolving over days to weeks (e.g., fungal, tuberculous, some atypical bacteria).
    • Chronic: Symptoms lasting >4 weeks.

Pathophysiology

• Mechanism: Pathogens typically gain access to the CNS via the bloodstream (hematogenous spread) after colonizing the nasopharynx or other sites. They cross the blood-brain barrier (BBB) by various mechanisms (e.g., direct endothelial injury, transcellular passage, "Trojan horse" mechanism within phagocytes). Once in the subarachnoid space, bacteria proliferate rapidly due to the poor host defenses (low immunoglobulin, complement, and phagocytic activity in CSF). This triggers a robust inflammatory response, leading to:
  • Release of inflammatory mediators (cytokines, chemokines, prostaglandins).
  • Increased permeability of the BBB, causing vasogenic edema.
  • Leukocyte influx into the CSF.
  • Cerebral edema (vasogenic, cytotoxic, interstitial).
  • Increased intracranial pressure (ICP).
  • Reduced cerebral blood flow (ischemia).
  • Neuronal injury and apoptosis.
• Risk Factors:
  • Extremes of Age: Neonates (immature immune system), elderly (waning immunity, comorbidities).
  • Immunocompromised States: HIV/AIDS, organ transplantation, chemotherapy, chronic steroid use, asplenia (functional or surgical), complement deficiencies.
  • Close Contact: Especially with individuals with meningococcal disease (e.g., college dorms, military barracks).
  • Lack of Vaccination: Unvaccinated or under-vaccinated status against Hib, S. pneumoniae, N. meningitidis.
  • Recent Infection: Otitis media, sinusitis, pneumonia, pharyngitis (can precede bacterial meningitis).
  • Anatomical Defects: Basilar skull fracture with CSF leak, neurosurgical procedures (shunts, external ventricular drains), penetrating head trauma, congenital CNS defects (e.g., dermal sinus).
  • Alcoholism, Diabetes, Chronic Liver/Kidney Disease: Increased susceptibility.
• Protective Factors:
  • Vaccination: Routine immunization against common bacterial causes (pneumococcal, meningococcal, Hib) is the most effective preventive measure.
  • Prompt Treatment of Local Infections: Early and effective treatment of otitis media, sinusitis, and pneumonia can prevent spread to the CNS.
  • Chemoprophylaxis: For close contacts of individuals with meningococcal meningitis or Hib disease.
  • Maintaining a Healthy Immune System: General health, nutrition, and avoiding unnecessary immunosuppression.

Clinical Presentation

Signs and Symptoms

• Cardinal Features (Classic Triad): Present in approximately 40-70% of bacterial meningitis cases.
  1. Fever: Typically high-grade.
  2. Headache: Severe, generalized, often throbbing.
  3. Nuchal Rigidity (Stiff Neck): Inability to flex the neck forward due to meningeal irritation.
• Other Common Symptoms:
  • Altered Mental Status: From lethargy and irritability to confusion, somnolence, and coma.
  • Photophobia: Sensitivity to light.
  • Phonophobia: Sensitivity to sound.
  • Nausea and Vomiting.
• Early Signs:
  • Often non-specific, resembling viral illness (malaise, myalgia, general fatigue).
  • In children, irritability, poor feeding, fussiness.
  • Rash: A petechial or purpuric rash is highly suggestive of meningococcal meningitis (seen in 50-60% of cases) and is a medical emergency.
• Advanced Signs (Indicative of Severe Disease or Complications):
  • Seizures: Can be focal or generalized.
  • Focal Neurological Deficits: Hemiparesis, cranial nerve palsies (e.g., III, IV, VI, VII, VIII).
  • Signs of Increased Intracranial Pressure (ICP): Papilledema (late sign), bradycardia, hypertension, irregular respirations (Cushing's triad – ominous sign).
  • Hydrocephalus.
  • Coma.
• Atypical Presentations:
  • Neonates/Infants: Subtle and non-specific symptoms such as poor feeding, lethargy, irritability, hypothermia or hyperthermia, vomiting, weak cry, bulging fontanelle, hypotonia, seizures. Nuchal rigidity may be absent.
  • Elderly/Immunocompromised: May present with subtle or absent fever, only mild headache, and primarily altered mental status (confusion, apathy, lethargy). Nuchal rigidity can be less prominent.
  • Viral Meningitis: Often milder symptoms, less severe altered mental status, sometimes without nuchal rigidity.

Physical Examination

• Inspection:
  • General appearance: Assess level of consciousness, signs of distress, lethargy, irritability.
  • Skin: Look for petechial or purpuric rash, especially over pressure points, trunk, and extremities. Ecchymoses may indicate disseminated intravascular coagulation (DIC).
  • Fontanelle (in infants): Assess for bulging or tension, indicating increased ICP.
• Palpation:
  • Pulse/Blood Pressure: Assess for signs of shock or Cushing's triad.
• Special Tests (for Meningeal Irritation):
  • Nuchal Rigidity: Inability or extreme difficulty in passively flexing the patient's neck (bringing chin to chest) due to spasm of the neck muscles. Pain and resistance are typically present.
  • Kernig's Sign: With the patient supine, flex the thigh on the abdomen with the knee flexed. Then, extend the leg at the knee. Pain and resistance to extension of the knee due to spasm of the hamstring muscles is a positive sign.
  • Brudzinski's Sign: With the patient supine, passively flex the neck forward. Involuntary flexion of the hips and knees is a positive sign.
  • Reliability: Kernig's and Brudzinski's signs have limited sensitivity (around 50-70% for both in adults with bacterial meningitis) but good specificity. Their absence does not rule out meningitis, especially in young children or the elderly.

Diagnostic Approach

History Taking

• Key Questions:
  • Symptom Onset and Progression: Acute vs. gradual, specific symptoms (fever, headache, stiff neck, AMS, rash).
  • Recent Illnesses: Upper respiratory tract infection, otitis media, sinusitis, pneumonia, skin infection, travel.
  • Exposures: Contact with sick individuals (especially children or those with meningitis), animal contact, insect bites.
  • Medical History: Immunocompromised status (HIV, malignancy, transplant, asplenia), diabetes, alcoholism, chronic organ disease, previous CNS infection, neurosurgical procedures, CSF leak (e.g., post-trauma).
  • Medications: Recent use of immunosuppressants, NSAIDs (can cause aseptic meningitis).
  • Vaccination Status: Against Hib, pneumococcus, meningococcus, mumps, measles, VZV.
  • Travel History: To areas endemic for specific pathogens (e.g., TB, fungal infections, arboviruses).
• Red Flags:
  • Rapid progression of symptoms.
  • Presence of petechial/purpuric rash.
  • Signs of increased ICP (depressed consciousness, focal neurological deficits, papilledema).
  • Immunocompromised state.
  • Extremes of age (neonates, elderly).

Laboratory Tests

• First-Line:
  • Lumbar Puncture (LP) and CSF Analysis: This is the cornerstone of diagnosis. CSF should be collected for:
    • Cell Count and Differential:
      • Bacterial: Markedly elevated WBC count (typically >1000 cells/µL), predominantly neutrophils (>80%).
      • Viral: Mildly elevated WBC count (typically 10-500 cells/µL), predominantly lymphocytes. Early viral meningitis can show neutrophil predominance.
      • Fungal/TB: Elevated WBC count (typically 50-500 cells/µL), predominantly lymphocytes.
    • Protein:
      • Bacterial: Elevated (>100 mg/dL, often >200 mg/dL).
      • Viral: Normal to mildly elevated (<100 mg/dL).
      • Fungal/TB: Elevated (often >100 mg/dL).
    • Glucose:
      • Bacterial: Low (<40 mg/dL or CSF/serum glucose ratio <0.4).
      • Viral: Normal (CSF/serum glucose ratio >0.6).
      • Fungal/TB: Low (often <40 mg/dL).
    • Gram Stain: Performed on centrifuged CSF. Positive in 60-90% of bacterial meningitis cases before antibiotics.
    • Bacterial Culture: Gold standard for bacterial meningitis, provides definitive pathogen identification and antimicrobial susceptibility.
  • Blood Cultures: Should be drawn prior to antibiotic administration. Positive in approximately 50-90% of bacterial meningitis cases.
  • Complete Blood Count (CBC): Leukocytosis with left shift common in bacterial infection.
  • Blood Glucose: Essential for interpreting CSF glucose ratio.
  • Basic Metabolic Panel: To assess for electrolyte abnormalities (e.g., SIADH) or renal dysfunction.
  • Inflammatory Markers: C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are often elevated in bacterial meningitis.
• Confirmatory:
  • CSF Culture: Definitive diagnosis for bacterial and fungal meningitis.
  • Polymerase Chain Reaction (PCR): Rapid and highly sensitive for specific bacterial (e.g., N. meningitidis, S. pneumoniae, L. monocytogenes) and viral (e.g., Enterovirus, HSV, VZV) pathogens in CSF. This is particularly useful for viral meningitis and for bacterial meningitis when Gram stain is negative or antibiotics have been started.
  • Cryptococcal Antigen (CrAg) Test: For fungal meningitis (especially in immunocompromised patients).
  • Acid-Fast Bacilli (AFB) Stain and Culture: For tuberculous meningitis.
  • Specific Antigen Tests: Latex agglutination tests for bacterial antigens (e.g., pneumococcal, meningococcal, Hib) are less commonly used now due to lower sensitivity and specificity compared to PCR.
• Monitoring:
  • Repeat LP: Generally not recommended unless there is clinical deterioration, failure to improve after 48-72 hours of therapy, or to ensure sterilization for highly resistant organisms or difficult-to-treat infections.
  • Serial Neurological Exams: To monitor for improvement or development of complications.
  • Inflammatory Markers: Can be used to trend response to therapy.

Imaging

• Recommended (CT scan of the head prior to LP): A non-contrast CT head should be performed before lumbar puncture if there are signs of increased ICP or risk factors for space-occupying lesions, to prevent cerebral herniation. Indications include:
  • Altered level of consciousness (Glasgow Coma Scale <10-11).
  • New onset seizure.
  • Focal neurological deficit (e.g., cranial nerve palsy, hemiparesis).
  • Papilledema.
  • Immunocompromised state (e.g., HIV, transplant, chronic steroids).
  • History of CNS disease (e.g., stroke, mass lesion, hydrocephalus, neurosurgery).
  • If a CT scan is indicated, blood cultures and empiric antibiotics (and dexamethasone) should be administered before the CT scan to avoid treatment delay. The LP can be performed safely after the CT rules out a mass lesion.
• Advanced (MRI of the brain):
  • More sensitive than CT for detecting subtle abnormalities and complications like cerebritis, brain abscesses, subdural effusions/empyema, hydrocephalus, venous sinus thrombosis, and ischemic changes.
  • Indicated if there are persistent focal neurological deficits, seizures, or lack of clinical improvement despite appropriate therapy, or to investigate atypical presentations.

Management

Acute Management

• Immediate (within 60 minutes of presentation):
  • Assess Airway, Breathing, Circulation (ABCs): Ensure patent airway, adequate ventilation, and hemodynamic stability. Provide supplemental oxygen.
  • Obtain Blood Cultures: Crucial before antibiotic administration.
  • Administer Empiric Antibiotics: Do not delay antibiotics while awaiting LP or CT, especially if bacterial meningitis is suspected.
  • Administer Dexamethasone: For bacterial meningitis, typically initiated before or with the first dose of antibiotics.
  • Consider LP (if safe): If no contraindications (as per CT indications above), perform LP immediately after blood cultures.
• Stabilization:
  • Fluid Management: Careful fluid resuscitation to maintain euvolemia. Avoid excessive hypotonic fluids to prevent exacerbating cerebral edema.
  • Antipyretics: To manage fever (acetaminophen, NSAIDs).
  • Seizure Management: If seizures occur, administer benzodiazepines (e.g., lorazepam 0.1 mg/kg IV, max 4 mg) followed by an antiepileptic drug (e.g., fosphenytoin 15-20 mg PE/kg IV, phenytoin).
  • Increased ICP Management:
    • Elevate head of bed 30 degrees.
    • Maintain normocapnia (avoid hyperventilation unless herniation is imminent).
    • Consider osmotic agents (e.g., mannitol 0.25-1 g/kg IV over 20-30 min, or hypertonic saline 3% 5-10 mL/kg IV over 10-30 min) for acute deterioration with signs of herniation.
• Emergency:
  • Rapid assessment of consciousness, vital signs, and neurological status.
  • Prompt recognition of septic shock (hypotension, tachycardia, poor perfusion) and initiation of vasopressors (e.g., norepinephrine) if fluid resuscitation is insufficient.
  • Management of respiratory failure (intubation and mechanical ventilation if needed).

Chronic Management

• Pharmacological:
  • Targeted Antimicrobial Therapy: Based on CSF Gram stain, culture, and susceptibility results. Duration varies by pathogen:
    • N. meningitidis: 7 days (e.g., Ceftriaxone)
    • S. pneumoniae: 10-14 days (e.g., Ceftriaxone/Cefotaxime, Vancomycin if resistant)
    • L. monocytogenes: ≥21 days (e.g., Ampicillin/Penicillin G + Gentamicin for synergy)
    • H. influenzae: 7 days (e.g., Ceftriaxone)
    • Viral Meningitis: Supportive care. Acyclovir 10-15 mg/kg IV q8h for 14-21 days if HSV or VZV is suspected/confirmed.
    • Fungal/TB Meningitis: Prolonged therapy (weeks to months) with specific antifungals (e.g., Amphotericin B, Fluconazole) or anti-TB regimens.
  • Anticonvulsants: Continue if seizures recur or if EEG indicates ongoing seizure activity.
• Non-pharmacological:
  • Rehabilitation: Physical, occupational, and speech therapy for patients with neurological deficits (e.g., paresis, ataxia, dysphasia).
  • Audiology Assessment: All patients, especially children, should undergo audiometric testing before hospital discharge due to the high risk of sensorineural hearing loss.
  • Psychological Support: For patients and families dealing with long-term sequelae.
• Monitoring:
  • Regular neurological assessments to monitor for improvement or new deficits.
  • Imaging (MRI) if there are ongoing focal deficits or to assess for complications like hydrocephalus or brain abscess.
  • Follow-up with infectious disease specialists and neurologists.

Treatment Algorithms

• First-Line (Empiric Antibiotics - Based on Age/Risk Factors - Administer Immediately!):
  • Neonates (<1 month): Ampicillin (100 mg/kg IV q8h) + Cefotaxime (50 mg/kg IV q8h) OR Ampicillin + Gentamicin.
  • Infants/Children (1 month - 18 years): Vancomycin (15 mg/kg IV q6h, max 60 mg/kg/day) + Ceftriaxone (100 mg/kg IV q24h or 50 mg/kg IV q12h, max 4 g/day) OR Cefotaxime (75 mg/kg IV q6h).
  • Adults (18-50 years): Vancomycin (15-20 mg/kg loading dose, then 15 mg/kg IV q8-12h, target trough 15-20 µg/mL) + Ceftriaxone (2 g IV q12h).
  • Adults (>50 years OR Immunocompromised OR Alcoholics): Vancomycin (as above) + Ceftriaxone (as above) + Ampicillin (2 g IV q4h) - to cover for Listeria monocytogenes.
  • Add Dexamethasone (for suspected bacterial meningitis): 10 mg IV q6h for 4 days in adults. 0.15 mg/kg IV q6h for 2-4 days in children. Start 15-20 minutes before or with the first dose of antibiotics. Strongly recommended for pneumococcal meningitis, controversial for other bacterial causes but generally given empirically.
• Second-Line (After Culture/Sensitivity Results):
  • Pathogen-Directed Therapy: Narrow spectrum to the most effective and least toxic agent.
    • N. meningitidis: Penicillin G or Ampicillin (if susceptible), or Ceftriaxone.
    • S. pneumoniae: Ceftriaxone/Cefotaxime (if susceptible), add Vancomycin if penicillin/ceftriaxone resistant.
    • L. monocytogenes: Ampicillin or Penicillin G (add Gentamicin for synergy in severe cases).
    • H. influenzae: Ceftriaxone.
  • Viral (HSV/VZV): Acyclovir 10-15 mg/kg IV q8h.
  • Fungal (Cryptococcal): Amphotericin B + flucytosine (induction), followed by high-dose fluconazole (consolidation/maintenance).
• Refractory Cases:
  • Re-evaluate diagnosis, consider non-infectious causes or unusual pathogens.
  • Confirm antibiotic sensitivity and CSF penetration.
  • Consider repeat LP.
  • Image the brain (MRI) for abscess, ventriculitis, hydrocephalus.
  • Consult infectious disease and neurosurgery if indicated.
  • Alternative antibiotics based on sensitivities, intrathecal therapy in specific cases.

Complications

• Common:
  • Hearing Loss: Sensorineural hearing loss (partial or complete, unilateral or bilateral) is common, especially with pneumococcal meningitis (up to 30% in children).
  • Seizures: Occur in up to 30% of cases, more common in children. Can be acute or develop later.
  • Cranial Nerve Palsies: Most commonly CN VI, VII, VIII (leading to strabismus, facial weakness, hearing loss/vertigo).
  • Hydrocephalus: Due to obstruction of CSF flow or impaired absorption.
  • Cognitive Impairment: Learning difficulties, memory problems, behavioral changes.
• Serious/Life-threatening:
  • Cerebral Edema and Increased ICP: Can lead to brain herniation and death.
  • Stroke: Due to vasculitis or thrombosis of cerebral vessels.
  • Brain Abscess/Subdural Empyema: Localized collections of pus.
  • Septic Shock and DIC: Especially with meningococcal meningitis (Waterhouse-Friderichsen syndrome).
  • SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion): Leading to hyponatremia.
  • Death: Despite advances in treatment, bacterial meningitis mortality remains 5-10% in adults and higher in neonates/elderly.
• Long-term:
  • Neurological sequelae (motor deficits, speech problems, visual impairment).
  • Epilepsy.
  • Developmental delay in children.
  • Psychological and behavioral issues.

Prognosis

• Factors Affecting Outcome:
  • Etiology: Bacterial meningitis has a worse prognosis than viral.
  • Age: Extremes of age (neonates, elderly) have worse outcomes.
  • Time to Treatment: Delayed initiation of appropriate antibiotics increases mortality and morbidity.
  • Pathogen: S. pneumoniae typically has a higher mortality rate and risk of sequelae compared to N. meningitidis. Listeria meningitis also carries a high mortality.
  • Severity of Illness at Presentation: Lower GCS score, presence of seizures, focal neurological deficits, signs of increased ICP, and septic shock are associated with worse prognosis.
  • Immunocompromised Status: Worse outcomes.
• Survival:
  • Bacterial Meningitis: Overall mortality rate around 5-10% in adults and children in developed countries. Can be up to 20-30% in specific populations (e.g., pneumococcal meningitis, elderly, immunocompromised).
  • Viral Meningitis: Generally excellent prognosis, with rare mortality except in severe cases (e.g., HSV encephalitis, mumps with complications, specific arboviruses).
• Quality of Life:
  • Approximately 20-30% of bacterial meningitis survivors experience long-term neurological sequelae, impacting their quality of life, including hearing loss, cognitive impairment, and seizures.
  • Viral meningitis typically has full recovery, but some patients may report post-meningitis syndrome (fatigue, headache, difficulty concentrating) for weeks to months.

Prevention

• Primary Prevention (Preventing Initial Occurrence):
  • Vaccination:
    • Streptococcus pneumoniae: Pneumococcal conjugate vaccines (PCV13, PCV20, PCV15) are part of routine childhood immunization and recommended for adults >65 years and those with certain risk factors (e.g., asplenia, chronic heart/lung disease, immunocompromise).
    • Neisseria meningitidis: Meningococcal conjugate vaccines (MCV4, MenACWY) for adolescents (routine at 11-12 years, booster at 16 years) and at-risk groups. Meningococcal B vaccines (MenB, Bexsero, Trumenba) for adolescents/young adults (16-23 years) and those at increased risk (e.g., complement deficiency, asplenia, during outbreaks).
    • Haemophilus influenzae type b (Hib): Hib conjugate vaccine is part of routine childhood immunization.
    • Other Vaccines: Mumps, measles, varicella-zoster vaccines also indirectly reduce the risk of meningitis caused by these viruses.
  • Chemoprophylaxis (for close contacts of meningococcal or Hib meningitis cases):
    • Meningococcal:
      • Rifampin: Adults: 600 mg PO q12h x 2 days. Children (≥1 month): 10 mg/kg PO q12h x 2 days. Infants (<1 month): 5 mg/kg PO q12h x 2 days.
      • Ceftriaxone: Adults: 250 mg IM single dose. Children (<15 years): 125 mg IM single dose. Preferred in pregnant women.
      • Ciprofloxacin: Adults: 500 mg PO single dose. Not for pregnant women or children.
    • Hib: Rifampin 20 mg/kg PO once daily (max 600 mg/day) for 4 days.
  • Hygiene: Hand hygiene, avoiding sharing personal items (drinks, utensils, cigarettes) especially in close living quarters.
  • Food Safety: For Listeria prevention, especially in pregnant women and immunocompromised individuals, avoid unpasteurized dairy products, soft cheeses, deli meats, and ensure proper cooking of food.
• Secondary Prevention (Early Detection and Intervention):
  • Rapid diagnosis and prompt initiation of appropriate antimicrobial therapy.
  • Early recognition and management of complications.
• Tertiary Prevention (Preventing Complications/Improving Outcomes):
  • Rehabilitation services for neurological deficits.
  • Audiology screening and intervention.
  • Long-term follow-up and management of chronic sequelae.

Special Populations

• Pediatric:
  • Neonates: High risk due to immature immune system. Atypical presentations (lethargy, poor feeding, bulging fontanelle, hypothermia). Primary pathogens: GBS, E. coli, Listeria. Empiric treatment: Ampicillin + Cefotaxime (or Gentamicin).
  • Infants/Children: Vaccination has dramatically reduced bacterial meningitis. Empiric treatment: Vancomycin + Ceftriaxone. Higher risk of hearing loss.
  • Fontanelle assessment is crucial in infants.
  • Dosages of medications must be adjusted for weight and age.
• Geriatric:
  • Increased risk of Listeria meningitis.
  • Often present with subtle symptoms (altered mental status, weakness, low-grade fever) and fewer meningeal signs.
  • Higher mortality and morbidity due to comorbidities and delayed diagnosis.
  • Empiric treatment must include coverage for Listeria (Ampicillin added to Vancomycin + Ceftriaxone).
• Pregnancy:
  • Increased susceptibility to Listeria monocytogenes (risk of fetal loss).
  • Avoid certain antibiotics (e.g., tetracyclines, fluoroquinolones). Ceftriaxone and Ampicillin are generally safe.
  • Dexamethasone use is generally considered safe if indicated.
  • Chemoprophylaxis for meningococcal contacts (Ceftriaxone preferred over Rifampin or Ciprofloxacin).
• Comorbidities (e.g., Immunocompromised, Asplenia):
  • Wider range of potential pathogens, including opportunistic infections (e.g., Listeria, Cryptococcus, Gram-negative bacilli).
  • Higher risk of severe disease and poor outcomes.
  • Broader empiric antibiotic coverage may be needed (e.g., adding anti-pseudomonal agent like Meropenem/Cefepime if hospital-acquired or highly immunocompromised).
  • Fungal meningitis is more common (e.g., Cryptococcus in HIV patients).

Clinical Pearls

• Diagnostic:
  • "Do not delay antibiotics for LP or CT." If bacterial meningitis is suspected, administer empiric antibiotics (and dexamethasone) immediately after blood cultures, especially if LP is delayed by imaging or clinical instability.
  • Consider CT before LP if any signs of increased ICP or risk for mass lesion are present (GCS <10-11, focal neuro deficit, new seizure, papilledema, immunocompromised, history of CNS disease).
  • A petechial or purpuric rash is a medical emergency and strongly suggests meningococcal meningitis; initiate treatment immediately.
  • CSF analysis is the gold standard for diagnosis. Be familiar with typical CSF profiles for bacterial vs. viral meningitis.
  • Remember atypical presentations in neonates, elderly, and immunocompromised patients. Absence of classic meningeal signs does not rule out meningitis.
• Treatment:
  • Dexamethasone timing is critical: Start before or with the first dose of antibiotics for bacterial meningitis to reduce inflammation and improve outcomes, especially in pneumococcal cases.
  • Empiric regimens are age-dependent and should cover the most likely pathogens. Always consider Listeria in older adults, neonates, and immunocompromised patients.
  • Once a pathogen and its sensitivities are known, narrow the antibiotic spectrum to reduce resistance and side effects.
  • Ensure adequate fluid management to avoid cerebral edema while maintaining cerebral perfusion.
  • For HSV meningitis, Acyclovir should be initiated empirically if suspicion is high, as it is a treatable viral cause.
• Pitfalls:
  • Delay in diagnosis or treatment: The most common and dangerous pitfall, directly impacting patient outcome.
  • Inadequate empiric antibiotic coverage: Failure to cover common pathogens, especially Listeria in at-risk groups.
  • Misinterpreting CSF results: Especially when partially treated or in early viral meningitis (neutrophil predominance can occur).
  • Over-reliance on negative meningeal signs: Kernig's and Brudzinski's signs are not sensitive enough to rule out meningitis.
  • Missing complications: Failure to monitor for and manage increased ICP, hydrocephalus, or hearing loss.

Recent Updates

• Guidelines:
  • Infectious Diseases Society of America (IDSA) Guidelines: Updated regularly (e.g., 2017 guidelines for adult bacterial meningitis, 2014 for pediatric). These provide comprehensive, evidence-based recommendations for diagnosis and management.
  • CDC Immunization Schedules: Regularly updated recommendations for pneumococcal and meningococcal vaccinations, including new vaccines (e.g., PCV20, MenB vaccines).
• Evidence:
  • Emerging Antibiotic Resistance: Ongoing surveillance of resistance patterns for S. pneumoniae and N. meningitidis influences empiric treatment recommendations (e.g., continued need for Vancomycin in empiric regimens for S. pneumoniae).
  • Diagnostic Modalities: Increased use of rapid molecular diagnostics (e.g., multiplex PCR panels for CSF) allows for quicker and more accurate pathogen identification, improving targeted therapy.
  • Vaccine Efficacy and Impact: Continued evidence demonstrating the profound impact of conjugate vaccines on reducing the incidence of invasive bacterial diseases.
  • Dexamethasone Use: Further studies continue to support its use, particularly for pneumococcal meningitis, but its benefit in other bacterial etiologies remains less clear, though often given empirically.
• Controversies:
  • Optimal Duration of Dexamethasone: While 4 days is standard, research continues on whether shorter courses may be equally effective in certain contexts.
  • Role of Dexamethasone in Non-Pneumococcal Bacterial Meningitis: Strongest evidence for S. pneumoniae, but often given empirically for all suspected bacterial meningitis given challenges in rapid differentiation.
  • Prophylactic Anticonvulsants: Not routinely recommended; only for those who have seizures.
  • Management of Viral Meningitis: Primarily supportive, but ongoing research into specific antiviral agents for non-HSV/VZV viral pathogens.

Key References

• Guidelines:
  • Tunkel AR, et al. Practice Guidelines for the Management of Bacterial Meningitis. Clinical Infectious Diseases. 2004;39(9):1267–1284. (Note: While an older guideline, it's foundational; newer updates from IDSA exist but may be specific to certain age groups or aspects).
  • IDSA Guidelines for the Management of Adults with Bacterial Meningitis (Published 2017).
  • IDSA Guidelines for the Management of Bacterial Meningitis in Infants and Children (Published 2014).
  • CDC Advisory Committee on Immunization Practices (ACIP) Recommendations (for up-to-date vaccination schedules).
• Studies:
  • de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002 Nov 14;347(21):1644-51. (Landmark study for dexamethasone benefit).
• Reviews/Textbooks:
  • Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases.
  • Harrison's Principles of Internal Medicine.
  • UpToDate (various topics on Meningitis).
  • The Sanford Guide to Antimicrobial Therapy.